Condition
Tumor Immunity
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (2)
P 2 (1)
Trial Status
Completed3
Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06844110Not ApplicableRecruitingPrimary
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
NCT04150744Phase 2RecruitingPrimary
RFA Plus Carrizumab vs Carrizumab Alone for HCC
NCT03872635Not ApplicableCompleted
Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period
NCT02771470Phase 1Completed
Intestinal Microflora in Lung Cancer After Chemotherapy
NCT02631993Completed
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
NCT02169388Phase 1Unknown
Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy
Showing all 6 trials